RT Journal Article
SR Electronic
T1 Association between SARS-CoV-2 Infection and Select Symptoms and Conditions 31 to 150 Days After Testing among Children and Adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.18.22283646
DO 10.1101/2022.12.18.22283646
A1 Zhang, Yongkang
A1 Romieu-Hernandez, Alfonso
A1 Boehmer, Tegan K.
A1 Azziz-Baumgartner, Eduardo
A1 Carton, Thomas W.
A1 Gundlapalli, Adi V.
A1 Fearrington, Julia
A1 Nagavedu, Kshema
A1 Dea, Katherine
A1 Moyneur, Erick
A1 Cowell, Lindsey G.
A1 Kaushal, Rainu
A1 Mayer, Kenneth H.
A1 Puro, Jon
A1 Rasmussen, Sonja A.
A1 Thacker, Deepika
A1 Weiner, Mark G.
A1 Saydeh, Sharon
A1 Block, Jason P.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/12/19/2022.12.18.22283646.abstract
AB Background An increasing number of studies have described new and persistent symptoms and conditions as potential post-acute sequelae of SARS-CoV-2 infection (PASC). However, it remains unclear whether certain symptoms or conditions occur more frequently among persons with SARS-CoV-2 infection compared with those never infected with SARS-CoV-2. We compared the occurrence of specific COVID-associated symptoms and conditions as potential PASC 31 to 150 days following a SARS-CoV-2 test among adults (≥20 years) and children (<20 years) with positive and negative test results documented in the electronic health records (EHRs) of institutions participating in PCORnet, the National Patient-Centered Clinical Research Network.Methods and Findings This study included 3,091,580 adults (316,249 SARS-CoV-2 positive; 2,775,331 negative) and 675,643 children (62,131 positive; 613,512 negative) who had a SARS-CoV-2 laboratory test (nucleic acid amplification or rapid antigen) during March 1, 2020–May 31, 2021 documented in their EHR. We identified hospitalization status in the day prior through the 16 days following the SARS-CoV-2 test as a proxy for the severity of COVID-19. We used logistic regression to calculate the odds of receiving a diagnostic code for each symptom outcome and Cox proportional hazard models to calculate the risk of being newly diagnosed with each condition outcome, comparing those with a SARS-CoV-2 positive test to those with a negative test. After adjustment for baseline covariates, hospitalized adults and children with a positive test had increased odds of being diagnosed with ≥1 symptom (adults: adjusted odds ratio[aOR], 1.17[95% CI, 1.11-1.23]; children: aOR, 1.18[95% CI, 1.08-1.28]) and shortness of breath (adults: aOR, 1.50[95% CI, 1.38-1.63]; children: aOR, 1.40[95% CI, 1.15-1.70]) 31-150 days following a SARS-CoV-2 test compared with hospitalized individuals with a negative test. Hospitalized adults with a positive test also had increased odds of being diagnosed with ≥3 symptoms (aOR, 1.16[95% CI, 1.08 – 1.26]) and fatigue (aOR, 1.12[95% CI, 1.05 – 1.18]) compared with those testing negative. The risks of being newly diagnosed with type 1 or type 2 diabetes (aHR, 1.25[95% CI, 1.17-1.33]), hematologic disorders (aHR, 1.19[95% CI, 1.11-1.28]), and respiratory disease (aHR, 1.44[95% CI, 1.30-1.60]) were higher among hospitalized adults with a positive test compared with those with a negative test. Non-hospitalized adults with a positive SARS-CoV-2 test had higher odds of being diagnosed with fatigue (aOR, 1.11[95% CI, 1.05-1.16]) and shortness of breath (aOR, 1.22[95% CI, 1.15-1.29]), and had an increased risk (aHR, 1.12[95% CI, 1.02-1.23]) of being newly diagnosed with hematologic disorders (i.e., venous thromboembolism and pulmonary embolism) 31-150 days following SARS-CoV-2 test compared with those testing negative. The risk of being newly diagnosed with certain conditions, such as mental health conditions and neurological disorders, was lower among patients with a positive viral test relative to those with a negative viral test.Conclusions Patients with SARS-CoV-2 infection were at higher risk of being diagnosed with certain symptoms and conditions, particularly fatigue, respiratory symptoms, and hematological abnormalities, after acute infection. The risk was highest among adults hospitalized after SARS-CoV-2 infection.Competing Interest StatementDr. Trick reported receiving grants from the Centers for Disease Control and Prevention (CDC) during the conduct of the study. No other disclosures were reported.Funding StatementThis publication was supported by Cooperative Agreement number 6-NU38OT000316, funded by the CDC. Drs. Zhang, Carton, Kaushal, Weiner, and Block also received funding from the National Institutes of Health (NIH) Agreement OTA HL161847-01 (contract number EHR-01-21) as part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative, which seeks to understand, treat, and prevent the post-acute sequelae of SARS-CoV-2 infection (PASC). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC), the RECOVER Program, or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This cohort study, included within a general SARS-CoV-2 surveillance project across PCORnet institutions, was deemed exempt from review under the public health surveillance provision of the Common Rule by the Harvard Pilgrim Health Care institutional review board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared publicly because of the use of the PCORnet data is under specific data use agreement, which requires IRB approval and PCROnet's review and approval. Data are available from the National Patient-Centered Clinical Research Network (https://pcornet.org/) for researchers who meet the criteria for access to confidential data. Researchers who are interested in using PCORnet data can request data via the established process. https://pcornet.org/front-door/